Eurofins Scientific SE's revenue for the
six
months ended in Dec. 2025 was $4,314 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $8,480 Mil.
Eurofins Scientific SE's Revenue per Share for the
six
months ended in Dec. 2025 was $23.38.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $45.48.
During the past 12 months, the average Revenue per Share Growth Rate of Eurofins Scientific SE was 9.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Eurofins Scientific SE's highest 3-Year average Revenue per Share Growth Rate was 38.40% per year. The lowest was 2.20% per year. And the median was 18.40% per year.
Eurofins Scientific SE (OTCPK:ERFSF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Revenue vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Revenue distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $8,480 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a Revenue of $8,480 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Eurofins Scientific SE and its competitors.
Is Eurofins Scientific SE's Revenue too high?
Eurofins Scientific SE's current Revenue is $8,480 Mil. Overall, Eurofins Scientific SE has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Revenue compare to TMO and DHR?
Eurofins Scientific SE's Revenue of $8,480 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Diagnostics & Research company?
A good Revenue depends on the Medical Diagnostics & Research industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Eurofins Scientific SE and its competitors. Eurofins Scientific SE's current Revenue is $8,480 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $78.60, compared to a current price of $79.35 — trading 1% above its estimated fair value. The current Revenue is $8,480 Mil. Eurofins Scientific SE's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Revenue is $8,480 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $79.35 is trading 1% above its estimated GF Value™ of $78.60.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Revenue: $8,480 Mil
GF Value™: $78.60 vs. price of $79.35 (1% above fair value)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
78GF Score
Get the complete analysis for ERFSF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
